Combination therapy to treat brain cancer
AssigneesInovio Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc.
InventorsAmy-Lee Bredlau, Israel Lowy, Jeffrey Skolnik, Jian Yan, Bernadette Ferraro, Jewell Walters
Life of this patent
Estimating the term…
Abstract
Provided herein are nucleic acid molecules, proteins, compositions and methods for treating brain cancer in a subject. In some embodiments, the compositions comprise cancer antigens hTERT, WT-1, and PSMA. In some embodiments, the compositions also comprise an adjuvant. The methods comprise administering to a subject in need thereof the cancer antigens. According to certain embodiments, the methods further involve administering the adjuvant and an anti-PD-1 antibody. In certain embodiments, the methods further comprise administering radiation therapy and/or a chemotherapeutic agent.
Claims28
An immunogenic composition comprising a plasmid encoding human telomerase reverse transcriptase (hTERT), a plasmid encoding Wilms Tumor-1 (WT-1), and a plasmid encoding prostate specific membrane antigen (PSMA).
A method of treating brain cancer in a subject, comprising administering to the subject:
- a plasmid encoding interleukin-12 (IL-12);
- an immunogenic composition of a plasmid encoding human telomerase reverse transcriptase (hTERT), a plasmid encoding Wilms Tumor-1 (WT-1), and a plasmid encoding prostate specific membrane antigen (PSMA);
- and
- an anti-programmed cell death receptor 1 (PD-1) antibody.
Dependencies are inferred from the claim text.